Figure 2.
Cost-effectiveness results for each intervention in comparison to no intervention. EB: endometrial biopsy; GS: genetic screening + EB, TVS (plus colonoscopy to early detect colorectal cancer); HBS: hypothetical biomarker panel screening including prolactin (sensitivity and specificity of 0.98, both); IUD: Levonorgestrel intrauterine device; LR: lifetime risk; OCPs: oral contraceptive pills; PBSO: prophylactic bilateral salpingo-oophorectomy; PH: prophylactic hysterectomy; TVS: transvaginal sonography. § associated with Lynch syndrome. * Including risk-reducing surgery (e.g., hysterectomy, PBSO, polypectomy to prevent colorectal cancer) in mutation carrier.
